The abstract is read at the publisher; the summary is JClub's.
TP53-mutated CHIP in 104 CAR-T recipients is linked to lower platelet and hemoglobin levels, higher baseline CAR-HEMATOTOX scores, and inferior clinical outcomes.
- Why it matters: CHIP’s immunologic relevance and its potential to shape CAR-T toxicities, inflammation, and survival are not well defined, limiting risk stratification.
- What they did: In an exploratory cohort of 104 CAR-T recipients, pre-existing CHIP clones were tracked with longitudinal serum inflammatory proteomics and clonal dynamics analyses.
- The result: Overall CHIP status was not associated with inflammatory toxicities or systemic inflammatory profiles, but TP53-mutated CHIP showed a distinct inflammatory signature and higher-risk behavior.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.